Inventor · disambiguated record
Axel Ullrich
Also filed as: ULLRICH AXEL
87 granted patents·28 pending applications·6,596 citations·filing 1981–2014
99Inventor score
Files withMAX PLANCK GESELLSCHAFT46GENENTECH INC22ULLRICH AXEL6MAX PLANCK GESSELLSCHAFT ZUR F5SUGEN INC5
Top patents by PatentIndex Score
115 records- 0199US6399063B1Monoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1998·Granted Jun 4, 2002·282 cites·18 claims
- 0299US6387371B1Monoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1999·Granted May 14, 2002·272 cites·14 claims
- 0399US6165464AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1998·Granted Dec 26, 2000·363 cites·11 claims
- 0499US5772997AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1995·Granted Jun 30, 1998·437 cites·13 claims
- 0599US5770195AMonoclonal antibodies directed to the her2 receptorGENENTECH INC·Filed 1995·Granted Jun 23, 1998·492 cites·36 claims
- 0699US5725856AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1995·Granted Mar 10, 1998·516 cites·26 claims
- 0799US5720954AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1995·Granted Feb 24, 1998·328 cites·35 claims
- 0899US5677171AMonoclonal antibodies directed to the HER2 receptorGENENTECH INC·Filed 1994·Granted Oct 14, 1997·924 cites·39 claims
- 0998US6015567AHER2 extracellular domainGENENTECH INC·Filed 1995·Granted Jan 18, 2000·283 cites·26 claims
- 1097US5720937AIn vivo tumor detection assayGENENTECH INC·Filed 1994·Granted Feb 24, 1998·224 cites·10 claims
- 1197US4859609ANovel receptors for efficient determination of ligands and their antagonists or agonistsGENENTECH INC·Filed 1986·Granted Aug 22, 1989·236 cites·15 claims
- 1295US6333169B1HER2 extracellular domainGENENTECH INC·Filed 1995·Granted Dec 25, 2001·151 cites·16 claims
- 1395US5990141ATreatment of platelet derived growth factor related disorders such as cancersSUGEN INC·Filed 1995·Granted Nov 23, 1999·189 cites·20 claims
- 1495US5851999AFLK-1 is a receptor for vascular endothelial growth factorMAX PLANCK GESELLSCHAFT·Filed 1995·Granted Dec 22, 1998·160 cites·32 claims
- 1594US4761371AInsulin receptorGENENTECH INC·Filed 1985·Granted Aug 2, 1988·168 cites·13 claims
- 1693US6326469B1Megakaryocytic protein tyrosine kinasesSUGEN INC·Filed 1995·Granted Dec 4, 2001·184 cites·11 claims
- 1793US6177401B1Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesisMAX PLANCK GESELLSCHAFT·Filed 1994·Granted Jan 23, 2001·123 cites·16 claims
- 1893US4440859AMethod for producing recombinant bacterial plasmids containing the coding sequences of higher organismsUNIV CALIFORNIA·Filed 1981·Granted Apr 3, 1984·170 cites·23 claims
- 1992US4933294AMethod of detecting truncated epidermal growth factor receptorsICRF PATENTS LIMITED·Filed 1985·Granted Jun 12, 1990·186 cites·8 claims
- 2091US6331555B1Treatment of platelet derived growth factor related disorders such as cancersUNIV CALIFORNIA·Filed 1999·Granted Dec 18, 2001·152 cites·15 claims
- 2190US7297774B2Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancerMAX PLANCK GESELLSCHAFT·Filed 2004·Granted Nov 20, 2007·26 cites·3 claims
- 2290US5030576AReceptors for efficient determination of ligands and their antagonists or agonistsGENENTECH INC·Filed 1989·Granted Jul 9, 1991·84 cites·7 claims
- 2388US7531304B2Method for screening FGFR-4 agonistsMAX PLANCK GESELLSCHAFT·Filed 2003·Granted May 12, 2009·35 cites·9 claims
- 2485US8043806B2Method of diagnosing an RTK-hyperfunction induced disorderMAX PLANCK GESELLSCHAFT·Filed 2010·Granted Oct 25, 2011·7 cites·7 claims
- 2585US6399331B2Method for culturing recombinant cellsGENENTECH INC·Filed 2000·Granted Jun 4, 2002·7 cites·29 claims
- 2684US5169762AHuman nerve growth factor by recombinant technologyGENENTECH INC·Filed 1988·Granted Dec 8, 1992·41 cites·17 claims
- 2784US4652525ARecombinant bacterial plasmids containing the coding sequences of insulin genesUNIV CALIFORNIA·Filed 1983·Granted Mar 24, 1987·50 cites·7 claims
- 2880US7678372B2Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancerMAX PLANCK GESELLSCHAFT·Filed 2003·Granted Mar 16, 2010·7 cites·11 claims
- 2979US8999982B2Pharmaceutically active compounds as Axl inhibitorsSCHULTZ-FADEMRECHT CARSTEN·Filed 2011·Granted Apr 7, 2015·10 cites·15 claims
- 3078US6872699B2Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 proteinMAX PLANCK GESELLSCHAFT·Filed 2001·Granted Mar 29, 2005·6 cites·4 claims
- 3178US6797513B2Nucleic acid encoding CLK2 protein kinasesMAX PLANCK GESELLSCHAFT·Filed 2001·Granted Sep 28, 2004·4 cites·8 claims
- 3278US6030822AExtracellular signal-regulated kinase, sequences, and methods of production and useMAX PLANCK GESELLSCHAFT·Filed 1995·Granted Feb 29, 2000·34 cites·6 claims
- 3377US5545533AMonoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodiesBOEHRINGER MANNHEIM GMBH·Filed 1995·Granted Aug 13, 1996·36 cites·4 claims
- 3476US6913894B2Antibodies directed against signal regulator proteinsEBERHARD KARLS UNI TUBINGEN UN·Filed 2002·Granted Jul 5, 2005·14 cites·4 claims
- 3575US5288622AHuman nerve growth factor by recombinant technologyGENENTECH INC·Filed 1992·Granted Feb 22, 1994·30 cites·9 claims
- 3674US5589375APTP 1D: a novel protein tyrosine phosphataseMAX PLANCK GESELLSCHAFT·Filed 1993·Granted Dec 31, 1996·31 cites·10 claims
- 3772US9011851B2Inhibitors of her3 activityULLRICH AXEL·Filed 2002·Granted Apr 21, 2015·6 cites·11 claims
- 3872US7034112B2Methods for diagnosis and treatment of MDK1 signal transduction disordersMAX PLANCK GESELLSCHAFT·Filed 2002·Granted Apr 25, 2006·2 cites·1 claims
- 3972US6235498B1Method for culturing recombinant cellsGENENTECH INC·Filed 1997·Granted May 22, 2001·14 cites·7 claims
- 4071US5932602ATreatment of platelet derived growth factor related disorders such as cancersSUGEN INC·Filed 1995·Granted Aug 3, 1999·26 cites·25 claims
- 4169US6004791AProtein tyrosine phosphatase PTP20 and related products and methodsMAX PLANCK GESELLSCHAFT·Filed 1997·Granted Dec 21, 1999·15 cites·11 claims
- 4269US5952212AProtein tyrosine phosphataseMAX PLANCK GESELLSCHAFT·Filed 1995·Granted Sep 14, 1999·19 cites·12 claims
- 4368US9458463B2Method for treatment of diabetes by a small molecule inhibitor for GRK5MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V·Filed 2014·Granted Oct 4, 2016·2 cites·9 claims
- 4468US5459036AExtracellular signal-regulated kinase, sequences, and methods of production and useMAX PLANCK GESELLSCHAFT·Filed 1993·Granted Oct 17, 1995·15 cites·18 claims
- 4567US5981251APTP 1D: a novel protein tyrosine phosphataseMAX PLANCK GESELLSCHAFT·Filed 1995·Granted Nov 9, 1999·15 cites·10 claims
- 4667US5677144ARecombinant DNA encoding CCK 2, a receptor tyrosine kinaseFiled 1994·Granted Oct 14, 1997·23 cites·25 claims
- 4765USRE39355EPreparation of human IGF via recombinant DNA technologyGENENTECH INC·Filed 2003·Granted Oct 17, 2006·0 cites·1 claims
- 4865US2006099708A1Methods for diagnosis and treatment of MDK1 signal transduction disordersMAX PLANCK GESELLSCHAFT·Filed 2005·Application pending·0 cites
- 4964US6770742B1Use of inhibitors for the treatment of disorders related to RTK hyperfunction, especially cancerMAX PLANCK GESELLSCHAFT·Filed 1999·Granted Aug 3, 2004·15 cites·1 claims
- 5064US6541615B1SIRP proteins and uses thereofMAX PLANCK GELLSCHAFT ZUR FODE·Filed 1997·Granted Apr 1, 2003·20 cites·17 claims
Showing the top 50 of 115 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Axel Ullrich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →